AlloVir (ALVR) Stock Forecast, Price Target & Predictions
ALVR Stock Forecast
AlloVir stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ALVR Analyst Ratings
According to 3 Wall Street analysts, AlloVir's rating consensus is 'Buy'. The analyst rating breakdown for ALVR stock is 1 'Strong Buy' (33.33%), 2 'Buy' (66.67%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 26, 2023 | Raymond James | Strong Buy | Strong Buy | Hold |
| Dec 26, 2023 | Wedbush | Buy | Buy | Hold |
| May 18, 2022 | Piper Sandler | Overweight | Overweight | Hold |
AlloVir's last stock rating was published by Raymond James on Dec 26, 2023. The company gave ALVR a "Strong Buy" rating, the same as its previous rate.
AlloVir Financial Forecast
AlloVir Revenue Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| # Analysts | - | - | - | - |
| Surprise % | - | - | - | - |
AlloVir's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ALVR's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
AlloVir EBITDA Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EBITDA | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
undefined analysts predict ALVR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than AlloVir's previous annual EBITDA (undefined) of $NaN.
AlloVir Net Income Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| Net Income | - | - | - | - |
| Avg Forecast | $-21.87M | $-13.82M | $-10.94M | $-11.87M |
| High Forecast | $-21.87M | $-13.82M | $-5.47M | $-11.87M |
| Low Forecast | $-21.87M | $-13.82M | $-15.31M | $-11.87M |
| Surprise % | - | - | - | - |
AlloVir's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ALVR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
AlloVir SG&A Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| SG&A | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
AlloVir's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ALVR last annual SG&A of $NaN (undefined).
AlloVir EPS Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EPS | - | - | - | - |
| Avg Forecast | $-0.19 | $-0.12 | $-0.10 | $-0.10 |
| High Forecast | $-0.19 | $-0.12 | $-0.05 | $-0.10 |
| Low Forecast | $-0.19 | $-0.12 | $-0.13 | $-0.10 |
| Surprise % | - | - | - | - |
According to undefined Wall Street analysts, AlloVir's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ALVR previous annual EPS of $NaN (undefined).
AlloVir Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ALVR | AlloVir | $0.75 | $34.00 | 4433.33% | Buy |
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| ANTX | AN2 Therapeutics | $1.06 | $8.75 | 725.47% | Buy |
| KRON | Kronos Bio | $0.94 | $7.63 | 711.70% | Buy |
| LYEL | Lyell Immunopharma | $1.39 | $9.50 | 583.45% | Hold |
| AVTE | Aerovate Therapeutics | $1.91 | $13.00 | 580.63% | Hold |
| BDTX | Black Diamond Therapeutics | $4.83 | $14.75 | 205.38% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| ACRV | Acrivon Therapeutics | $7.60 | $22.00 | 189.47% | Buy |
| FDMT | 4D Molecular Therapeutics | $16.16 | $44.57 | 175.80% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.27 | $6.00 | 164.32% | Buy |
| MLYS | Mineralys Therapeutics | $11.98 | $30.00 | 150.42% | Buy |
| STOK | Stoke Therapeutics | $15.12 | $33.75 | 123.21% | Buy |
| ADAG | Adagene | $2.33 | $5.00 | 114.59% | Buy |
| CGEM | Cullinan Oncology | $17.24 | $32.00 | 85.61% | Buy |
| MRUS | Merus | $50.10 | $77.86 | 55.41% | Buy |
| CRNX | Crinetics Pharmaceuticals | $52.99 | $70.14 | 32.36% | Buy |
| AGIO | Agios Pharmaceuticals | $45.69 | $47.50 | 3.96% | Buy |
| ANAB | AnaptysBio | $37.50 | $36.33 | -3.12% | Buy |
ALVR Forecast FAQ
Is AlloVir a good buy?
Yes, according to 3 Wall Street analysts, AlloVir (ALVR) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of ALVR's total ratings.
What are AlloVir's analysts' financial forecasts?
AlloVir's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-36.624M (high $-31.156M, low $-40.999M), average SG&A $0 (high $0, low $0), and average EPS is $-0.318 (high $-0.271, low $-0.356). ALVR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-21.874M (high $-21.874M, low $-21.874M), average SG&A $0 (high $0, low $0), and average EPS is $-0.19 (high $-0.19, low $-0.19).